These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 19401540)

  • 21. Antiarrhythmic therapy in atrial fibrillation.
    Ravens U
    Pharmacol Ther; 2010 Oct; 128(1):129-45. PubMed ID: 20624425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New directions in antiarrhythmic drug therapy for atrial fibrillation.
    Heijman J; Voigt N; Dobrev D
    Future Cardiol; 2013 Jan; 9(1):71-88. PubMed ID: 23259476
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Atrial-Selective Potassium Channel Blockers.
    Voigt N; Dobrev D
    Card Electrophysiol Clin; 2016 Jun; 8(2):411-21. PubMed ID: 27261831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacologic TWIK-Related Acid-Sensitive K+ Channel (TASK-1) Potassium Channel Inhibitor A293 Facilitates Acute Cardioversion of Paroxysmal Atrial Fibrillation in a Porcine Large Animal Model.
    Wiedmann F; Beyersdorf C; Zhou X; Büscher A; Kraft M; Nietfeld J; Walz TP; Unger LA; Loewe A; Schmack B; Ruhparwar A; Karck M; Thomas D; Borggrefe M; Seemann G; Katus HA; Schmidt C
    J Am Heart Assoc; 2020 May; 9(10):e015751. PubMed ID: 32390491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can inhibition of IKur promote atrial fibrillation?
    Burashnikov A; Antzelevitch C
    Heart Rhythm; 2008 Sep; 5(9):1304-9. PubMed ID: 18774108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vernakalant in the management of atrial fibrillation.
    Cheng JW
    Ann Pharmacother; 2008 Apr; 42(4):533-42. PubMed ID: 18334607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Model systems for the discovery and development of antiarrhythmic drugs.
    Nattel S; Duker G; Carlsson L
    Prog Biophys Mol Biol; 2008; 98(2-3):328-39. PubMed ID: 19038282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New drugs targeting the cardiac ultra-rapid delayed-rectifier current (I Kur): rationale, pharmacology and evidence for potential therapeutic value.
    Ford JW; Milnes JT
    J Cardiovasc Pharmacol; 2008 Aug; 52(2):105-20. PubMed ID: 18670369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacologic inhibition of small-conductance calcium-activated potassium (SK) channels by NS8593 reveals atrial antiarrhythmic potential in horses.
    Haugaard MM; Hesselkilde EZ; Pehrson S; Carstensen H; Flethøj M; Præstegaard KF; Sørensen US; Diness JG; Grunnet M; Buhl R; Jespersen T
    Heart Rhythm; 2015 Apr; 12(4):825-35. PubMed ID: 25542425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiarrhythmic Mechanisms of SK Channel Inhibition in the Rat Atrium.
    Skibsbye L; Wang X; Axelsen LN; Bomholtz SH; Nielsen MS; Grunnet M; Bentzen BH; Jespersen T
    J Cardiovasc Pharmacol; 2015 Aug; 66(2):165-76. PubMed ID: 25856531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope?
    Ehrlich JR; Nattel S
    Curr Opin Cardiol; 2009 Jan; 24(1):50-5. PubMed ID: 19077816
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atrial fibrillation: Therapeutic potential of atrial K
    Ravens U; Odening KE
    Pharmacol Ther; 2017 Aug; 176():13-21. PubMed ID: 27742566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cardiac two-pore-domain potassium channels (K2P): Physiology, pharmacology, and therapeutic potential].
    Schmidt C; Wiedmann F; Schweizer PA; Katus HA; Thomas D
    Dtsch Med Wochenschr; 2012 Aug; 137(33):1654-8. PubMed ID: 22875694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Atria-selective antiarrhythmic drugs in need of alliance partners.
    Peyronnet R; Ravens U
    Pharmacol Res; 2019 Jul; 145():104262. PubMed ID: 31059791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel ion channel targets in atrial fibrillation.
    Hancox JC; James AF; Marrion NV; Zhang H; Thomas D
    Expert Opin Ther Targets; 2016 Aug; 20(8):947-58. PubMed ID: 26918581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Potassium channels and arrhythmia].
    Funck-Brentano C
    Arch Mal Coeur Vaiss; 1992 Dec; 85 Spec No 4():9-13. PubMed ID: 1307198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Electrical remodeling in atrial fibrillation.
    Dobrev D
    Herz; 2006 Apr; 31(2):108-12; quiz 142-3. PubMed ID: 16738832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of chronic gap junction conduction-enhancing antiarrhythmic peptide GAP-134 administration on experimental atrial fibrillation in dogs.
    Laurent G; Leong-Poi H; Mangat I; Moe GW; Hu X; So PP; Tarulli E; Ramadeen A; Rossman EI; Hennan JK; Dorian P
    Circ Arrhythm Electrophysiol; 2009 Apr; 2(2):171-8. PubMed ID: 19808462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potassium channel blocking 1,2-bis(aryl)ethane-1,2-diamines active as antiarrhythmic agents.
    Kajanus J; Antonsson T; Carlsson L; Jurva U; Pettersen A; Sundell J; Inghardt T
    Bioorg Med Chem Lett; 2019 May; 29(10):1241-1245. PubMed ID: 30879840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of atrial fibrillation with doxapram: TASK-1 potassium channel inhibition as a novel pharmacological strategy.
    Wiedmann F; Beyersdorf C; Zhou XB; Kraft M; Paasche A; Jávorszky N; Rinné S; Sutanto H; Büscher A; Foerster KI; Blank A; El-Battrawy I; Li X; Lang S; Tochtermann U; Kremer J; Arif R; Karck M; Decher N; van Loon G; Akin I; Borggrefe M; Kallenberger S; Heijman J; Haefeli WE; Katus HA; Schmidt C
    Cardiovasc Res; 2022 Jun; 118(7):1728-1741. PubMed ID: 34028533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.